Provectus Biopharma Proxy: Executive Pay & Equity Awards Detailed
Ticker: PVCT · Form: DEF 14A · Filed: May 1, 2025 · CIK: 315545
| Field | Detail |
|---|---|
| Company | Provectus Biopharmaceuticals, Inc. (PVCT) |
| Form Type | DEF 14A |
| Filed Date | May 1, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-compensation, proxy-statement, equity-awards
Related Tickers: PVCT
TL;DR
Provectus Biopharma DEF 14A out: Executive pay details and equity awards for 2024 are now public.
AI Summary
Provectus Biopharmaceuticals, Inc. filed its DEF 14A on May 1, 2025, detailing executive compensation for the fiscal year ending December 31, 2024. The filing includes information on compensation for its principal executive officers and directors, as well as grants of equity awards. Specific dollar amounts for compensation and equity awards are detailed within the proxy statement.
Why It Matters
This filing provides shareholders with crucial information about how executive compensation is structured and awarded, impacting corporate governance and investor confidence.
Risk Assessment
Risk Level: medium — DEF 14A filings primarily concern executive compensation and corporate governance, which can indirectly impact stock performance but do not typically involve immediate financial risks.
Key Numbers
- 2024 — Fiscal Year (Executive compensation and equity awards reported for this year.)
- 2023 — Fiscal Year (Comparative compensation data may be available for this year.)
- 2022 — Fiscal Year (Comparative compensation data may be available for this year.)
Key Players & Entities
- PROVECTUS BIOPHARMACEUTICALS, INC. (company) — Filer
- 0000315545 (company) — Central Index Key
- 20250501 (date) — Filing Date
- 2024-12-31 (date) — Fiscal Year End
FAQ
What is the total compensation for the Named Executive Officers (NEOs) in fiscal year 2024?
The filing details compensation for NEOs, but specific total dollar amounts for 2024 are not provided in the summary data; the full proxy statement contains these figures.
What types of equity awards were granted to executives in 2024?
The filing indicates that equity awards were granted to PEO members, with 'GrantDateFairValueOfEquityAwardsGrantedDuringTheYearMember' data points for 2024, 2023, and 2022.
Who are the Named Executive Officers (NEOs) of Provectus Biopharmaceuticals for the reporting period?
The filing refers to 'ecd:PeoMember' and 'ecd:NonPeoNeoMember' which represent executive and non-executive officer compensation components, but specific names of NEOs are not listed in the provided summary.
What is the company's fiscal year end?
The company's fiscal year ends on December 31st, as indicated by 'FISCAL YEAR END: 1231'.
When was this DEF 14A filing submitted to the SEC?
This DEF 14A filing was submitted to the SEC on May 1, 2025, as indicated by 'FILED AS OF DATE: 20250501'.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on May 1, 2025 regarding PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT).